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1. Introduction 
With a prevalence of about 4.4 million women and a lethality rate of more than 410,000 cases 
per year, breast cancer is the most common cancer disease and the leading cause of death in 
women worldwide (Mangiapane et al., 2008). Advances in early detection and improved 
treatment for breast cancer have led to a steady decrease in the overall breast cancer 
mortality rate. However, breast cancer remains a significant cause of morbidity and 
mortality. In general, breast cancer is categorized into the estrogen receptor (ER)–positive 
type and the ER-negative type, based on the prevalence of ERs within the cell. About 70-80% 
of all breast cancers are estrogen sensitive and they are treated by conventional procedures 
including surgery, radiation chemotherapy, and estrogen analogues. Results from clinical 
trials have demonstrated that it is possible to prevent estrogen-responsive breast cancers by 
targeting the ER with selective modulators (i.e. tamoxifen, raloxifene, or lasofoxifene) or 
with aromatase inhibitors (i.e. anastrozole, letrozole, or exemestene). While the ER-positive 
tumors respond to anti-estrogen therapy and have better prognosis, the ER-negative tumors 
are more aggressive and resistant to treatments (Uray & Brown, 2006; Li & Brown, 2007; 
Cuzick, 2008). The high aggressiveness and therapeutic resistance of ER-negative breast 
tumors have made necessary the development of new and efficient strategies for their 
prevention and/or treatment.  
Recently, the World Cancer Research Fund/American Institute for Cancer Research has 
reported that changes in diet and lifestyle are good strategies for cancer prevention. 
Evidence based on a systematic review of the published literature has demonstrated benefits 
of diet modification approach to reduce cancer risk (Greenwald & Dunn, 2009). The rising 
prevalence of cancer worldwide and the corresponding rise in health care costs is propelling 
interest among researchers and consumers for multiple health benefits of food compounds, 
including reduction in cancer risk and modification of tumor behavior (Béliveau, 2007; 
Kaefer and Milner, 2008). A large number of natural compounds present in the diet have 
been demonstrated to lower breast cancer risk and sensitize tumor cells to anti-cancer 
therapies (Kaefer & Milner, 2008; Ramos, 2008; Hauner & Hauner, 2010). Among these 
dietary compounds, those present in plant foods and collectively termed phytochemicals, 
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have been identified as the most promising chemopreventive agents. They may affect 
different targets of the signal transduction pathways that modulate gene expression, cell 
cycle progression, proliferation, metabolism and/or apoptosis (Ramos, 2008; van Breda et 
al., 2008). High priority should be given to research aimed at the study of natural 
compounds that could potentially prevent the development of breast cancer in susceptible 
patients. 
1.1 Role of dietary compounds against estrogen-receptor negative breast cancer 
It is well-known that endocrine interventions are not an effective strategy to reduce the risk 
of ER-negative breast cancers (Uray & Brown, 2006; Li & Brown, 2007; Cuzick, 2008). Thus, 
in the last few years, the searching and development of chemopreventive agents against ER-
negative breast cancer are attracting more attention. Recently, a number of novel 
chemopreventive agents targeting non-endocrine pathways have been developed and their 
capacity to prevent ER-negative mammary tumorigenesis has been demonstrated (Li & 
Brown, 2007). These agents include retinoids, cyclooxygenase-2 inhibitors, tyrosine kinase 
inhibitors, and growth factors. Further studies have shown the other compounds possess 
critical role on cell growth of ER-negative breast cancer, such as retinoid X receptors, 
vitamin D receptors, peroxisome proliferator-activated receptors, n-3 polyunsaturated fatty 
acids (PUFA) and several phytochemicals (Simeone & Tari, 2004; Uray & Brown, 2006; 
Spencer et al., 2009). This chapter is focused on those dietary compounds that have 
demonstrated a promising potential as chemopreventive agents against ER-negative breast 
cancer. These compounds, including vitamins, lipids, phytochemicals, proteins and 
bioactive peptides, have been reported to provide important protection against initiation, 
promotion or progression of breast cancer. Effects of these compounds as well as their 
mechanism of action are summarized in this chapter, as shown in Table 1. Moreover, special 
attention is given to peptide lunasin, identified in soybean and other plants, and which 
chemopreventive properties against breast cancer have been recently demonstrated.  
1.1.1 Vitamins 
Retinoids is a family of compounds that include both natural and synthetic derivatives of 
vitamin A or retinol. They have been found to play important regulatory roles in cellular 
proliferation, development, metabolism and differentiation (Gudas et al., 1994). It has been 
reported that these compounds prevent carcinogenesis in a variety of tissues including the 
breast (Yang et al., 1999). All-trans-retinoic acids (ATRA), the oxidized form of retinol, 
inhibit the proliferation of breast cancer cells predominantly by blocking the transition from 
G1 to S phase, and activating proteasome function, caspase cleavage and apoptosis (Toma et 
al., 1997; Son et al., 2007). The main mechanisms of 4-haptoglobin-related protein’s apoptotic 
action have been associated with nitric oxide and reactive oxygen species production, 
ceramide function, and mitochondrial permeability transition (Simeone & Tari, 2004). 
Recently, it has shown a rapid decrease of histone H3 acetylation at position Lys 9 at the 
human telomerase reverse transcriptase promoter. It could be an important mechanism by 
which ATRA shuts down telomerase activity, thus mediating its antitumor effects in ER-
negative breast cancer cells (Phipps et al., 2009). Unfortunately, their side effects, including 
hyperlipidaemia, muco-cutaneous and liver toxicity, have limited their extensive use in 
humans (Lee et al., 1993). Therefore, there is a growing body of studies developing novel 
synthetic retinoids or combination therapies to decrease their toxicity and increase their  
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efficacy against breast cancer (Gediya et al., 2008). Several clinical studies using retinoids as 
breast cancer chemopreventive agents are currently undergoing. Phase III clinical trials are 
showing that retinoids potently reduced incidence of second breast malignancies in 
premenopausal women (Bonanni et al., 2007).  
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3), the biologically active form of vitamin D, is not 
only a secosteroid hormone essential for bone and mineral homeostasis but also it is a 
compound exerting a number of biological functions. Epidemiological investigations 
indicate that higher level of vitamin D intake is inversely associated with breast cancer 
risk (Shin et al., 2002). In contrast, an epidemiological study carried out in 107 countries 
has demonstrated that deficiency in vitamin D increases the risk of breast cancer (Mohr et 
al., 2008). Recently, it has also been demonstrated that vitamin D deficiency promotes the 
growth of human breast cancer MDA-MB-231-TxSA cells in a murine model of malignant 
bone lesions (Ooi et al., 2010). Treatment of 1,25(OH)2D3 has been found to decrease 
RelB/RELB gene expression and pro-survival targets Survivin, MnSOD and Bcl-2 levels, 
and to stimulate the MAP-kinases ERK1 and ERK2 activity in both ER-positive MCF-7 
cells and ER-negative MDA-MB-231 breast cancer cells (Mineva et al., 2009; Cordes et al., 
2006). Vitamin D affects different pathways, such as cell cycle, apoptosis, hormone 
receptors, angiogenesis, and hypoxia, all of which are related to the breast cancer growth, 
progression and metastasis by mechanisms independent of estrogen signaling. Moreover, 
vitamin D may have synergistic, additive, or antagonistic effects when combined with 
other therapeutic agents against breast cancer (Flanagan et al., 2003; Bertone-Johnson, 
2009). Well-designed clinical trials should be needed to further address whether vitamin 
D is likely to play an important role in reducing risk, mortality and recurrence of breast 
cancer.  
1.1.2 Dietary lipids 
Relationship between breast cancer and dietary lipids has been extensively studied. Studies 
in animal models and observations in humans have provided evidence that a high intake of 
n-6 PUFAs stimulate several stages in the development of mammary cancer, from an 
increase in oxidative DNA damage to effects on cell proliferation, free estrogen levels to 
hormonal catabolism (Bartsch et al., 1999). In contrast, fish oil-derived n-3 PUFAs, such as 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), seem to prevent cancer by 
influencing the activity of enzymes and proteins related to intracellular signaling, and 
ultimately cell proliferation. Recently, it has been demonstrated that these n-3 PUFAs exert 
potent anti-inflammatory, anti-apoptotic, anti-proliferative and anti-angiogenic effects 
(Spencer et al., 2009). These authors have reported that these compounds act through 
regulation of several growth factors, cyclooxygenase 2 (COX-2), prostaglandin-E2 (PGE2), 
nitric oxide, nuclear factor kappa beta (NF-κB), matrix metalloproteinases (MMP) and beta-
catenin. Mandal and co-workers (2010) used a xenograft metastasis MDA-MB-231 mouse 
model, demonstrating that fish oil diet prevents the formation of osteolytic lesions in bone 
by inhibiting pro-metastatic molecule CD44 expression both in mRNA and protein levels. It 
has been also shown that both DHA and EPA significantly reduce surface expression of 
CXCR4 and attenuate the migration/invasion of MDA-MB-231 cells in vitro (Altenburg and 
Siddiqui, 2009; Mandal et al., 2010). Recently, Blanckaert et al. (2010) reported that n-3 
PUFAs have anti-proliferative effect, induce apoptosis via a transient increase in caspase-3 
activity, promote nuclear condensation, and reduce the invasive potential of MDA-MB-231 
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cells. Flaxseed is the richest source of n-3 PUFA alpha-linolenic acid among the vegetable 
oils. Chen et al. (2002) have shown that nude mice fed flaxseed enriched diet inhibited the 
MDA-MB-435 human breast cancer growth and metastasis in a xenograft model, and this 
effect was partly due to its down-regulation of insulin-like growth factor I and epidermal 
growth factor receptor expression. These studies indicate that naturally occurring n-3 
PUFAs are emerging because of their potential to increase efficacy to breast cancer treatment 
without having any additional side effects. 
Abundant epidemiological studies have attributed a potential chemopreventive effect to 
extra-virgin olive oil, rich in antioxidants and monounsaturated fatty acids (MUFA) such as 
oleic acid, which is associated with low incidence and mortality rates from cardiovascular 
disease and some cancers, including breast cancer (Escrich et al., 2007). Interestingly, a 
negative modulatory role of a high-virgin olive oil diet in the appearance and progression of 
experimental breast cancer has been described (Escrich et al., 2007). Moreover, mammary 
tumors from animals fed this kind of diet not only showed a benign clinical behavior but 
also a lower degree of morphological malignancy compared with control and high n-6 fat 
diet (Costa et al., 2002; Escrich et al., 2006). Oleic acid as well as other minor components 
could contribute for the biological effects of olive oil on the distinct carcinogenesis stages 
through different molecular mechanisms of action. 
1.1.3 Phytochemicls 
The low incidence of breast cancer among Asians may be explained in part by dietary 
habits. Epidemiological and experimental studies have shown convincing evidence that 
people consuming phytoestrogens-rich diets have lower incidence and mortality of breast 
cancer (Messina & Flickinger, 2002). Asian diets are rich in soybean products containing 
different compounds found to provide important protection against initiation, promotion 
and/or progression of breast cancer (Messina et al., 2006). These include isoflavones, 
saponins, phenolic acids, phytosterols, protease inhibitors, and bioactive proteins and 
peptides, such as lectins and lunasin.  
Genistein, daidzein and glycitein are the three major isoflavonoids, with a chemical 
structure similar to estrogens, found in soybean and soy products which properties have 
been extensively studied (Park and Surh, 2004). Genistein has been identified as the 
predominant isoflavone contained in soybean. Accumulating experiments have concluded 
that genistein functions as a promising carcinogenesis inhibitor through different molecular 
mechanisms of action (Banerjee et al., 2008). In addition to its estrogenic effects, genistein 
has been reported to possess anti-carcinogenic effect through an ER independent pathway, 
thus being beneficial for ER-negative breast cancer. Genistein possesses free radicals 
scavenging activity, inhibits the expression of stress-response related genes, and inhibits the 
growth of several cancer cell lines through the modulation of genes intimately related to the 
regulation of cell cycle and apoptosis (Vissac-Sabatier et al., 2003; Liao et al., 2004). 
Mutations of the onco-suppressor genes BRCA1 and BRCA2 are associated with a 
hereditary risk of breast cancer. It has been demonstrated that genistein or daidzein 
treatments up-regulate BRCA1 and BRCA2 gene expression and modulate the different 
genes involved these pathways, such as BAX, RB1, BRIP and p53 in both MCF-7 and MDA-
MB-231 cells, suggested a potential chemopreventive effect in promoting apoptosis and 
maintenance of genome stability (Caëtano et al., 2006; Bernard-Gallon et al., 2010). Genistein 
also intervenes in several cellular transduction signaling pathways and involves in the 
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regulation of gene activity by modulating epigenetic events such as DNA methylation 
and/or histone acetylation (Banerjee et al., 2008; Gaur & Bhatia, 2009). Puerariae radix is a 
popular natural herb and a traditional food in Asia. Isoflavones contained in this plant 
induce cell apoptosis through a caspase-3-dependent pathway and mediate cell cycle arrest 
in the G2/M phase in HS578T, MDA-MB-231 and MCF-7 cell lines (Lin et al., 2009). 
Recently, it has demonstrated that the flavonols quercetin and kaempferol have higher anti-
invasion potency and higher MMP-3 inhibitory activity than genistein, genistin and 
daidzein in the MDA-MB-231 cells (Phromnoi et al., 2009). Phytochemicals, ingested 
through soybean or other legumes, exerts anti-carcinogenic effects through pleiotropic 
molecular mechanisms of action on cell cycle, apoptosis, angiogenesis, invasion and 
metastasis. As an adjuvant therapy in many chronic diseases like cancer, its use is almost 
established due to less or no side effects. 
Epidemiological studies have shown that consumption of green tea polyphenols (GTP) 
reduces the incidence and progression of breast cancer. An inverse association between the 
risk of breast cancer and the intake of green tea has also been reported in Asian Americans. 
The breast cancer progression is delayed in the Asian population that consumes green tea on 
regular basis (Wu et al., 2003). Green tea is an important source of antioxidants that may be 
useful for chemoprevention of cancer. It was demonstrated that treatments of GTP and its 
principal constituent epigallocatechin gallate (EGCG) significantly induce apoptosis and 
decrease invasion of MDA-MB-231 cells, through beta-catenin and AKT signaling pathway 
modulation (Thangapazham et al., 2007a). Moreover, both GTP and EGCG treatments had 
the ability to arrest the cell cycle at G1 phase by down-regulation the protein expression of 
cyclin D, cyclin E, cyclin-dependent kinases (CDK) 4, CDK 1 and PCNA. In an in vivo study, 
nude mice were inoculated with MDA-MB-231 cells and treated with GTP and EGCG, 
observing that these compounds were effective in delaying the tumor incidence as well as 
reducing the tumor burden compared to the control group (Thangapazham et al., 2007b). 
The tumor sections were also observed that GTP and EGCG induce apoptosis and inhibit 
cell proliferation by immunohistochemistry analysis. Similarly, indole-3-carbinol, abundant 
in cruciferous vegetables, induces apoptosis inhibiting phosphorylation and activation of 
protein kinase B/Akt, and decreasing NF-κB DNA binding activity in the tumor-derived 
ER-alpha-negative breast cell line MDA-MB-468 (Howells et al., 2002). 
1.1.4 Food peptides 
Natural peptides have attracted attention as drug candidates owing to their possession of 
certain key advantages over alternative chemotherapy molecules. In contrast to most small-
molecule drugs, peptides have high affinity, strong specificity for targets and low toxicity. 
Moreover, peptides have good penetration of tissue due to the small size, thus attractive as 
alternative cell surface targeting agents for cancer therapy (Bhutia and Maiti, 2008). Proteins 
and peptides have become one group of nutraceuticals exerted biological functions that 
shows potential results in preventing the different stages of cancer including initiation, 
promotion and progression (de Mejia and Dia, 2010). Recently, there has been increased 
interest in the potential health benefits of different food proteins and peptides, including 
plant protease inhibitors, lactoferrin and lactoferricin, lectins and lunasin.  
Protease inhibitors, found in plant tissues particularly legumes, act as possible protective 
agents against several types of cancer, such as breast cancer. The Bowman-Birk inhibitor 
(BBI) is a soybean-derived protease inhibitor with 71 amino acids that has been shown to be 
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an effective suppressor of carcinogenesis in both in vitro and in vivo assays (Losso, 2008). The 
role of BBI in carcinogenesis was evaluated either as a purified BBI or as BBI concentrate 
(BBIC). BBI is involved in inflammation processes, decreases the amount of oxidative 
damage, and suppresses carcinogenesis by affecting the amount of certain types of 
proteolytic activities or the expression of certain proto-oncogenes. BBIC achieved 
Investigational New Drug status from the FDA in 1992, and human trials are currently 
undergoing to evaluate its use as an anticarcinogenic agent for prostate and oral carcinomas 
(Armstrong et al., 2000, 2003; Malkowicz et al., 2001). Although BBI has a broad spectrum of 
cancer-protective activities, its effects on breast cancer remains limited. Treatment of BBI 
was effective in preventing 7,12-dimethylbenz[a]anthracene (DMBA)-induced 
transformation using mouse mammary glands in culture system (Du et al., 2001). However, 
no in vivo study reporting the effect of BBI as breast cancer preventive peptide has been 
published. Nevertheless, there are some in vitro studies showing that BBI decreased 
estrogen-dependent human breast cancer cell growth. These studies demonstrated that 
suppressed proliferation of MCF-7 cells through abating proteasome function that resulted 
in up-regulation of MAP kinase phosphatase-1, which turns to suppress ERK1/2 activity 
and induce apoptosis and lysosome membrane permeabilization (Zhang et al., 1999; Chen et 
al., 2005; Joanitti et al., 2010). Kunitz trypsin inhibitor (KTI) is another protease inhibitor 
originally isolated from soybean. The biological significance of this protein in carcinogenesis 
is mainly attributed to suppress invasion and metastasis of cancer cells (de Mejia and Dia, 
2010). KTI isolated from seeds of Chinese black soybean, suppressed proliferation of MCF-7 
cells and HepG2 hepatoma cells (Ye and Ng, 2009). However, there are few data about the 
role of protease inhibitors against ER-negative breast cancer. 
Lactoferrin, a globular glycoprotein with a molecular mass of 80 kDa, is a multifunctional 
protein of the transferrin family that is widely represented in various secretory fluids, such 
as milk, saliva, tears, and nasal secretions (Lönnerdal, 2009). Early study showed that bovine 
and human lactoferrin had no effect on growth of MCF-7 cells and only a minimal inhibitory 
activity toward the MDA-MB-231 line was observed (Hurley et al., 1994). Lactoferrin 
induces growth arrest at the G1 to S transition, through decreasing protein levels of CDK2 
and cyclin E. CDK2 and CDK4 kinase activities are also decreased and p21 expression is 
increased, maintaining the retinoblastoma protein (Rb) in a hypophosphorylated form in 
MDA-MB-231 cells and other epithelial cell lines such as HBL-100, MCF-7 and HT-29 
(Damiens et al., 1999). Recently, Duarte et al. (2011) has also provided evidences that bovine 
lactoferrin decreases the cell viability and cell migration, and increases apoptosis in HS578T 
and T47D cells. Bovine lactoferricin is a cationic peptide produced by gastric-pepsin 
hydrolysis of bovine lactoferrin, with potent cytotoxic activity against cancer cells (Bellamy 
et al., 1992). Lactoferricin caused DNA fragmentation and morphological changes consistent 
with apoptosis in MDA-MB-435 cell cultures, but did not affect the viability of 
untransformed mammary epithelial cells (Furlong et al., 2006). Although the mechanisms of 
action are not fully known, the results gathered in this work suggest that lactoferricin 
interferes with some of the most important steps involved in cancer development. 
Extensive studies have revealed that a number of lectins from plants can be used for 
prevention and/or treatment of cancer. Soy lectins are a significant group of biologically 
active glycoproteins that have been shown to possess cancer chemopreventive activity by in 
vitro, in vivo and human case studies (de Mejia et al., 2003). A sialic acid-specific lectin has 
been purified from the mushroom Paecilomyces Japonica, which exerts cell cytotoxic effects on 
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the human breast cancer MDA-MB-231, human stomach cancer SNU-1 and pancreas cancer 
AsPc-1 cells (Park et al., 2004). The suggested mechanisms of action for lectins include 
effects on membranes of tumor cells, reducing cell proliferation and inducing apoptosis, as 
well as effects on macrophages increasing their tumor-specific cytotoxicity. Another 
potential mechanism of action includes lectins’s effects on the immune system by altering 
the production of various interleukins (de Mejia and Prisecaru, 2005). GAP31 (Gelonium 
protein of 31 kDa) and MAP30 (Momordica protein of 30 kDa) are glycoproteins isolated 
from the medicinal plants Gelonium multiflorum and Momordica charantia, respectively. Lee-
Huang et al. (2000) conducted a study demonstrated the efficacy of GAP31 and MAP30 
inhibiting MDA-MB-231 cells proliferation and expression of HER2 gene, and also 
increasing survival delayed tumor development in human breast cancer bearing SCID mice. 
Moreover, some dietary lectins can inhibit cell growth of human breast cancer MCF-7, T47D, 
HBL100 and BT 20 cells in vitro, suggesting a protective effect of these plant lectins for breast 
cancer (Valentiner et al., 2003). There is still much to learn about the effects of plant lectins 
on cancer risk. However, they are currently being used as therapeutics agents in cancer 
treatment studies and this area of research holds considerable potential.  
2. Lunasin’s discovery and beyond 
Lunasin is a peptide composed of 43 amino acid residues with a MW of 5.5 kDa, which 
sequence is SKWQHQQDSCRKQKQGVNLTPCEKHIMEKIQGRGDDDDDDDDD. It was 
initially identified in the soybean cotyledon when a cDNA encoding for a post-
translationally processed 2S-albumin (Gm2S-1) was cloned from mid-maturation soybean 
seed (Galvez et al., 1997). Gm2S-1 coded not only for the methionine-rich protein that was 
sought to promote the nutritional quality of soy protein but also for other three proteins, a 
signal peptide, a linker peptide, and a small subunit. This subunit was termed lunasin from 
the Tagalog word "lunas" for cure. Galvez and co-workers observed that transfection and 
constitutive expression of the lunasin gene into mammalian cells disrupted mitosis and 
induced chromosomal fragmentation and apoptosis (Galvez and de Lumen, 1999). The 
authors attributed lunasin’s effects to its negatively charged poly-D carboxyl end that could 
bind to the highly basic histones found within the nucleosomes of condensed chromosomes, 
probably to regions that contain more positively charged, such as the hypoacetylated 
chromatin found in telomeres and centromeres. The displacement by lunasin of the 
kinetochore proteins normally bound to the centromeres could lead to the failure of spindle 
fiber attachment and eventually to mitotic arrest and cell death. In addition, lunasin 
contains the sequence RGD, a cell adhesion motif, that is responsible for the attachment of 
lunasin to extracellular matrix (Galvez and de Lumen, 1999) thereby allowing its 
internalization in mammalian cells within a few minutes and its localization in the nucleus 
in approximately 18 h (Lam et al., 2003). The tri-peptide RGD is the cell attachment site 
recognized by integrins present in extracellular matrix and cell surface proteins (Ruoslahti 
and Pierschbacher, 1986). Previous studies have shown the role of RGD peptides inducing 
apoptosis in different cell lines via a caspase-dependent mechanism (Matsuki et al., 2008; 
Anuhadra et al., 2000). This motif has been also found to cause cytotoxicity in established 
human cancer cell lines, including HL 60 (Anuhadra et al., 2000).  
Lunasin has been identified in soybean and other beans, grains and herbal plants, such as 
wheat, barley, rye, amaranth, sunberry, wonderberry, bladder-cherry and jimson weed etc., 
at concentrations ranged from 0.013 to 8.1 mg lunasin/g of protein (Jeong et al., 2002; de 
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Mejia et al., 2004; Jeong et al., 2007a, 2007b, 2007c; Silva-Sanchez et al., 2008; Jeong et al., 
2009; Jeong et al., 2010a). Lunasin’s concentration in seeds and its products has been 
reported to depend on the genotype varieties, some environmental factors, such as 
temperature and soil moisture, and the processing conditions (de Mejia et al., 2004; Wang et 
al, 2008). The stages of seed development have also been found to affect lunasin’s 
concentration, and thus, a notable increase of this concentration has been found to happen 
during seed maturation. However, the content of lunasin is continually decrease 
accompanied with the soaking time of sprouting, but is not affected by light and dark 
conditions (Park et al., 2005). Recently, it has been found that environmental factors, such as 
germination time and temperature has a significant influence on the composition and 
concentration of bioactive compounds in germinated soybean flour from the Brazilian 
soybean cultivars BRS 133 and BRS 258 (Paucar-Menacho et al., 2010b, c). These authors 
reported that protein concentration also affect the final distribution of nutrients and 
bioactive components in soybean, including lunasin (Paucar-Menacho et al., 2010a). 
A first study has demonstrated lunasin’s presence in US commercially available soy foods, 
including soy milk, infant formulas, tofu, bean curd, soybean cake, tempeh, and su-jae 
(Hernández-Ledesma et al., 2009a). Concentrations of this peptide in soy milk and other 
soybean products seem to be determined by the soybean variety and the process used 
during manufacturing, indicating that these two parameters can be used to control contents 
of these two peptides. Previously it had been demonstrated that large-scale processing of 
soy to produce different protein fractions influences lunasin concentration. This content 
varied from 12 to 44 mg lunasin/g of flour when different commercially available soy 
proteins were analyzed (de Mejia et al., 2004; Jeong et al., 2003).  
2.1 Lunasin’s bioavailability 
Oral administration of an anti-carcinogenic agent has been recognized as a plausible and 
cost-effective approach to reduce cancer morbidity and mortality by inhibiting precancerous 
events before the occurrence of clinical disease (Prasain & Barnes, 2007). Since lunasin is a 
peptide, it is crucial to establish whether it, once orally ingested, survives digestion and gets 
absorbed, reaching the target tissues and organs in an intact and bioactive state. Lunasin’s 
bioavailability has been demonstrated by both in vitro and in vivo studies. Preliminary 
bioavailability studies carried out in mice and rats fed lunasin-enriched soy protein have 
found that 35% of ingested lunasin reaches the target tissues and organs in an intact and 
active form (Jeong et al., 2007a, 2007b). Park and coworkers carried out in vitro studies 
demonstrating the role of proteases inhibitors, such as BBI and KTI, in protecting lunasin 
from digestion by gastrointestinal enzymes when soy protein was orally consumed (Park et 
al., 2007). This protection plays a major role in making lunasin bioavailable in soy protein. 
Recently, it has been demonstrated that lunasin extracted from the blood and liver of 
lunasin-enriched soy diet fed rats is bioactive and able to suppress foci formation as 
synthetic lunasin does (Hsieh et al., 2010a). Lunasin’s bioavailability has been also reported 
in a human study. Dia and co-workers demonstrated 4.5% of lunasin ingested in the form of 
soy protein reached plasma of healthy volunteer men (Dia et al., 2009a). The capacity of 
lunasin to survive degradation by gastrointestinal and serum proteinases and peptidases 
reaching blood and other organs in a bioactive form, make lunasin as a perfect candidate to 
exert a potent in vivo cancer preventive activity.  This fact supports future clinical trials to 
investigate the chemopreventive activities of lunasin.  
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2.2 Lunasin’s chemopreventive properties against breast cancer 
Lunasin’s chemopreventive activities have been demonstrated by both in vitro and in vivo 
studies. In vitro studies have demonstrated that cancer preventive properties of this peptide 
in mammalian cells induced by chemical carcinogens and viral oncogenes. In vivo studies, 
lunasin’s preventive properties have also been confirmed in both skin and a breast cancer 
mouse model induced by a chemical carcinogen. Recently, it has been demonstrated that 
lunasin exerts a promising role against breast cancer both by using MDA-MB-231 cell 
culture and a breast cancer xenograft mouse model. Lunasin’s chemopreventive properties 
against ER-negative breast cancer and its possible mechanisms are described in this section. 
2.2.1 In vitro lunasin’s chemopreventive properties – Mechanism of action 
Lunasin was considered as a “watchdog” agent that sits in the nucleus of the cells and 
effectively does nothing when there is no transformation event. When a transformation 
event occurs, lunasin is triggered into action (de Lumen, 2005). Interestingly, recent studies 
have revealed that lunasin also acts on well-established cancer cell lines. Up to one third on 
breast cancers that are initially ER-independent making tumors resistant to endocrine 
therapy during tumor progression (Im et al, 2008). Due to this emergence of hormone-
resistance, it is necessary to search for alternative therapies. Lunasin has been demonstrated 
to inhibit cell proliferation in ER-negative breast cancer MDA-MB-231 cells in a dose-
dependent manner, showing an IC50 value of 181 µM (Hsieh et al., 2010b). Studies carried 
out to establish a structure/activity relationship showed an IC50 value of 138 µM for the 21 
amino acid sequence localized at the C-terminus of lunasin, thus being the main responsible 
for lunasin’s inhibitory effect on breast cancer cells proliferation (Hernandez-Ledesma et al., 
2011). Possible mechanisms of action have been recognized as responsible for lunasin’s 
chemopreventive action against breast cancer (Figure 1). First studies demonstrated that 
lunasin inhibits histone acetylation that is considered as one of the most important 
epigenetic modifications acting on signal transduction pathways involved in cancer 
development (Dwarakanath et al., 2008; Dalvai and Bystricky, 2010). Early mistargeted and 
deregulated histone acetyltransferase (HATs) activities occurring in the common tumor 
types, such as breast cancer might determine the subsequent genetic changes leading to 
tumor development and progression (Gayther et al., 2000; Stearns et al., 2007). Because 
epigenetic changes may be reversible, they represent an active area for new drug 
investigation and are promising targets for cancer therapy. Therefore, accumulating studies 
focus on investigating and developing the HATs modulators either for mechanistic studies 
or for anticancer values. 
When the cells are in the steady-state conditions, the core H3 and H4 histones are mostly 
deacetylated, as a repressed state. After cells treatment with lunasin and sodium butyrate, a 
known deacetylase inhibitor, the process of histone acetylation was found to be inhibited in 
C3H10T1/2 fibroblasts and MCF-7 breast cancer cells (Galvez et al., 2001; Jeong et al., 2003). 
Furthermore, lunasin has demonstrated to compete with different HATs, such as yGCN5 
and PCAF, inhibiting the acetylation and repressing the cell cycle progression (Jeong et al., 
2002, 2007a, 2007b). According to these findings, an epigenetic mechanism of action for 
lunasin has been proposed. This model reveals that lunasin can selectively kill cells that are 
being transformed or are newly transformed when tumor suppressor proteins, like Rb, p53 
and pp32, are inactivated by chemical carcinogens and/or viral oncogenes. When lunasin is 
present in the nucleus, it is acting as a surrogate tumor suppressor and tightly binding to  
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Fig. 1. 
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deacetylated core histones and disrupting the balance between acetylation-deacetylation, 
which is perceived by the cell as abnormal and leads to cell death (de Lumen, 2005). 
Recently, we have demonstrated that lunasin is a potent inhibitor of H3 and H4 histone 
acetylation (Hernández-Ledesma et al., 2011). This activity was higher than that 
demonstrated by other compounds, such as anacardic acid and curcumin, which 
chemopreventive properties have been demonstrated (Balasubramanyam et al., 2003, 2004a, 
2004b). Studies focused on elucidating lunasin’s structure-activity relationship establish that 
lunasin’s sequence is essential for inhibiting H4 acetylation whereas poly-D sequence is the 
main active sequence responsible for H3 acetylation inhibition (Hernández-Ledesma et al., 
2011).  
Acetylation of specific lysine residues in histones is generally linked to chromatin disruption 
and the transcriptional activation of genes (Strahl & Allis, 2000). A plethora of chromatin 
alterations appears to be responsible for the development and progression of various types 
of cancers, including breast cancer. A global histone modification analysis revealed that in 
the majority of breast cancers, histone H4 acetylation at position Lys16 was reduced or 
absent, suggesting that this alteration may represent an early sign of breast cancer (Fraga et 
al., 2005). In addition, moderate to low levels of histone H3 acetylation at positions Lys9 and 
Lys18, and histone H4 acetylation at Lys12 were observed in breast carcinomas, and they 
were associated with poor prognosis and clinical outcome (Elsheikh et al., 2009). Therefore, 
evaluation of inhibitory effect on specific lysine residues of histones seems to be very 
promising for searching new therapies against breast cancer. A dose-dependent inhibitory 
effect on H4 acetylation at positions H4-Lys 8 and H4-Lys 12 was observed after addition of 
lunasin to breast cancer MDA-MB-231 cells, reaching 17% and 19% for both positions, 
respectively, when lunasin was treated at 75 µM (Hernández-Ledesma et al., 2011). It should 
be needed to extensively study the relevance of these results on lunasin’s chemopreventive 
activity to provide data about lunasin’s molecular mechanism of action on epigenetic 
alterations that would be very useful to define new prognostic markers and therapeutic 
targets. 
Studies conducted in our laboratory have revealed different mechanisms of action than 
histone acetylation inhibition. We have demonstrated that lunasin modulates expression of 
different genes and proteins involved in cell cycle, apoptosis and signaling transduction 
(Hsieh et al., 2010b). Inhibition of deregulated cell cycle progress in cancer cells is being 
considered an effective strategy to delay or halt tumor growth. The cell cycle is regulated 
through the sequential activation and inactivation of CDKs that drive cell cycle progression 
(Kato et al., 1993). A pivotal regulatory pathway determining rates of cell cycle transition 
from G1 to S phase is the CCN/CDK/p16/RB pathway. Over-expression of cyclins D1 and 
D3 is one of the most frequent alterations present in breast tumors. Cyclins D interacts with 
CDK4 or CDK6 to form a catalytically active complex, which phosphorylates RB to free 
active E2F (Sutherland and Musgrove, 2004). Up-regulatory lunasin’s effect of RB gene 
expression (Hsieh et al., 2010b), as well as its inhibitory effect of RB phosphorylation (Jeong 
et al., 2007b), suggest that both transcriptional and post-translational modifications may be 
responsible for lunasin’s inhibitory effect on cancer cell cycle progression. Moreover, lunasin 
has been found to inhibit cell proliferation, arrest the cell cycle in the S phase in 45% and 
down-regulated the mRNA levels of CDk2, CDk4, CDC25A, Caspase 8, and Ets2, Myc, 
Erbb2, AKT1, PIK3R1 and Jun signaling genes in MDA-MB-231 cells (Hsieh et al., 2010b, 
2011a). Lunasin was also demonstrated to reduce protein levels of cyclin D1, cyclin D3, 
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CDK4 and CDK6 in a dose-dependent form in these breast cancer cells (Hernández-
Ledesma et al., 2011), that might also contribute on this lunasin’s suppressive effect. This 
action also affects cell cycle control pathway, especially in the G1/S phase arrest. However, 
further research should be needed to elucidate the complete molecular and epigenetic 
lunasin’s mechanism of action in breast cancer and other type of cancer cell lines. 
Inflammation and oxidative stress are two of the most critical factors implicated in 
carcinogenesis and other degenerative disorders. Accumulating evidences have revealed 
that chronic inflammation is involved in the development of approximately 15–20% of 
malignancies worldwide (Kuper et al., 2000), being clearly associated with increased cancer 
risk and progression (Allavena et al, 2008). In the last years, there was an increasing body of 
evidence supporting the role of COX-2 in breast cancer development and progression. COX-
2 has been found to be inappropriately induced and up-regulated in human breast cancer. 
Molecular studies have linked over-expression of COX-2 to a number of critical components 
of breast carcinogenesis including mutagenesis, angiogenesis, inhibition of apoptosis and 
aromatase-catalysed oestrogen biosynthesis. Moreover, high levels of COX-2 have been also 
associated with poor prognosis (Ristimäki et al., 2002; Singh-Ranger et al., 2008). Lunasin 
has been found to exert anti-inflammatory activity that might contribute to its 
chemopreventive properties against breast cancer. First studies demonstrated that lunasin 
potently inhibits lipopolysaccharide-induced production of pro-inflammatory mediators 
interleuquine-6, tumor necrosis factor-α, and PGE2 in macrophage cells (Hernández-
Ledesma et al., 2009b), through modulation of COX-2/PGE2 and inducible nitric oxide 
synthase/nitric oxide pathways, and suppressing of NF-κB pathways (Dia et al., 2009b; de 
Mejia & Dia, 2009). Larkins and co-workers (2006) have demonstrated that COX-2 inhibition 
can decrease breast cancer cells motility, invasion and matrix metalloproteinase expression. 
Abnormally up-regulated COX and PGs expression are features in human breast tumors, so 
lunasin might have a role in treatment and prevention of this kind of cancer.  
Large amounts of reactive oxygen species (ROS) have been shown to participate in the 
etiology of several human degenerative diseases, including inflammation, cardiovascular 
and neurodegenerative disorders, and cancer (Ames et al., 1993). Oxidative stress and ER-
associated proliferative changes are suggested to play important roles in estrogen-induced 
breast carcinogenesis. Several transcription factors and tumor suppressors are involved 
during stress response such as Nrf2, NFκB and BRCA1 (Acharya et al., 2010). 
Physiologically achievable concentrations of estrogen or estrogen metabolites have been 
shown to induce ROS production. Estrogen-induced ROS by increasing genomic instability 
and by transducing signal through influencing redox sensitive transcription factors play 
important role in cell transformation, cell cycle, migration and invasion of the breast cancer 
(Okoh et al., 2011). Lunasin has also been found to exert potent antioxidant properties, 
reducing lipopolysaccharide-induced production of ROS by macrophage cells, and acting as 
a potent free radical scavenger (Hernández-Ledesma et al., 2009b). Recently, lunasin 
purified from Solanum nigrum L. has been found to protect DNA from oxidative damage by 
suppressing the generation of hydroxyl radical via blocking fenton reaction (Jeong et al., 
2010b).  
2.2.2 In vivo lunasin’s chemopreventive properties  
Lunasin’s role as chemopreventive agent against breast cancer has also been demonstrated 
in in vivo mouse models. Our first findings show a relevant inhibitory effect on mammary 
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tumors development when a lunasin-enriched diet was administered to DMBA-induced 
SENCAR mice (Hsieh et al., 2010c). Six-week-old SENCAR mice were fed experimental diets 
before, during and after DMBA treatment by gavage once per week for 6 weeks, until they 
were sacrificed at 24-week-old. Tumor generation and tumor incidence were reduced by 
38% and 25%, respectively, in the mice fed with lunasin-enriched diet (containing 0.23% 
lunasin) compared with control group. Moreover, the tumor sections obtained from mice 
fed the lunasin-enriched diet showed slight stromal invasion and degree of morphological 
aggressiveness due to the effect of this peptide contained in the soy protein preparation 
(Hsieh et al., 2010c). Park and co-works have reported that an isoflavone-deprived soy 
peptides prevent DMBA-induced rat mammary tumorigenesis, as well as inhibits the 
growth of human breast cancer MCF-7 cells in a dose-dependent manner, and induce cell 
death (Park et al., 2009). Lunasin might be responsible for the effects reported by these 
authors.  
A recent study has demonstrated that lunasin reduces tumor incidence and generation in a 
xenograft mouse model using human breast cancer MDA-MB-231 cells (Hsieh et al., 2010a). 
The nude mice were intraperitoneal injected with lunasin, at 20 mg/kg and 4 mg/kg body 
weight three times per week for two months, and then transplanted with MDA-MB-231 cells 
and followed up for the other seven weeks. The tumor incidence was 49% and 33%, 
respectively, in the two doses of lunasin groups compared to the control group. The tumor 
generation was significantly reduced in the lower dose of lunasin group by 70% lower 
relative to control group. Lunasin’s inhibitory effect was also found on the tumor weight 
and volume. In contrast, injection with BBI at 20 mg/kg body weight showed no effect on 
tumor development. The breast tumor histological sections obtained from the lunasin group 
showed cell proliferative inhibition and cell apoptosis induction. These mice studies show 
lunasin as promising alternative to prevent and/or treat skin and breast cancer. Further 
research should be needed to demonstrate chemopreventive role of this peptide against 
other types of cancer, as well as to elucidate its in vivo mechanism of action. 
2.2.3 Lunasin’s combinations as a novel strategy against breast cancer 
Cancer chemotherapeutic strategies commonly require multiple agents. Combination of two 
or more chemopreventive agents is becoming the best strategy to prevent and/or treat 
cancer because of its ability to achieve greater inhibitory effects on cancer cells with lower 
toxicity potential on normal cells (Li et al., 2005; de Kok et al., 2008). Studies based on 
molecular mechanisms are needed to optimize this combination, increasing tumor response 
and reducing toxicity levels in non-cancerous cells (de Kok et al., 2008).  
Aspirin (acetylsalicylic acid) has been demonstrated as one of the most promising agents 
with chemopreventive efficacy against several types of cancer. However, aspirin use has 
been associated with undesirable side effects, peptic ulcer complications, particularly 
bleeding and mucosal injury in the stomach, small intestine, and colon (Lanas et al., 2000; 
Laine, 2006). In an attempt to increase aspirin’s efficacy and to avoid its side effects, some 
researchers have explored the potentially beneficial effects of its combination with several 
agents that may produce synergisms, resulting in considerably stronger protective effects 
against carcinogenesis than individually agent use. Since lunasin is present in various seeds 
and food products, and no safety concerns have been noted. Hsieh and co-workers (2010b) 
have demonstrated that lunasin promotes the cell proliferation inhibitory and apoptosis 
inducing activities of aspirin in human breast cancer MDA-MB-231 cells (Hsieh et al., 
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2010b). Significant synergistic effects were observed when 10 µM lunasin was combined 
with 0.5 mM aspirin, resulting in a 73% reduction of cell number. This synergistic effect, at 
least partially, was mediated through modulating the expression of genes encoding G1 and 
S-phase regulatory proteins and the extrinsic-apoptosis dependent pathway. Synergistic 
down-regulatory effects were observed for ERBB2, AKT1, PIK3R1, FOS and JUN signaling 
genes, whose amplification has been reported as being responsible for breast cancer cell 
growth and resistance to apoptosis. Moreover, additional studies have demonstrated that 
lunasin/aspirin combination inhibits foci formation and cell proliferation in chemical 
carcinogens DMBA and MCA induced-NIH/3T3 cells (Hsieh et al., 2011b). The effect was 
notably higher than that observed when compounds of the combination acted as a single 
agent.  
Anacardic acid (6-pentadecylsalicylic acid), found in the shell of the cashew nut, has been 
linked to anti-oxidative, anti-microbial, anti-inflammatory and anti-carcinogenic activities 
(Kubo et al., 1993; Sung et al., 2008). Synergistic effects have also been observed when 
lunasin (1–25 µM) was combined with anacardic acid (25 to 100 µM) to treat human breast 
cancer MDA-MB-231 cells resulting in a concentration-dependent inhibition (Hsieh et al., 
2011a). Our findings revealed that lunasin/anacardic acid combination arrests cell cycle in 
S-phase and induces apoptosis at higher levels than that observed when each compound is 
used individually. This combination also promotes the inhibition of ERBB2, AKT1/PI3K, 
JUN and RAF1 signaling gene expression. Importantly, lunasin is demonstrated to promote 
the anti-carcinogenic properties of anacardic acid, suggesting the role of lunasin is not only 
in cancer prevention, but also in cancer auxiliary therapy.  
Lunasin enhances anti-cancer ability of other chemopreventive compounds from natural or 
synthetic sources, making them perfect candidate strategies to prevent and/or treat breast 
cancer. The safety and efficacy of chronic use of these combinations should be further tested 
in animal models and human studies to establish the optimal dose and duration of 
treatment. Moreover, studies derived from these findings about mechanisms of action of 
these lunasin’s combinations would open a new vision in the development of novel 
therapies against breast cancer.  
3. Conclusion / Future perspectives 
Breast cancer is the most common cancer disease and the leading cause of death in women 
worldwide. Different food compounds have been demonstrated to be effective against this 
type of cancer. Among them, peptide lunasin is becoming as one of the most promising 
agents. This peptide, found in soybean and other plants, has been demonstrated to be 
bioavailable after resisting gastrointestinal and serum degradation, and to reaches blood 
and target organs in an intact and active form. Lunasin has been shown to act as a 
promising agent against breast cancer in both in vitro and in vivo assays. This peptide 
inhibits ER-independent breast cancer MDA-MB-231 cells proliferation and promotes other 
chemopreventive agents’ activities, inhibiting proliferation and inducing apoptosis. 
Moreover, lunasin reduces tumor incidence in a chemical carcinogen-induced mammary 
tumor and in a xenograft breast cancer mouse model. Moreover, genomics, proteomics and 
biochemical tools are being applied to complete elucidate its molecular mechanism of action. 
An array of mechanisms have been revealed for this peptide, including antioxidant and anti-
inflammatory properties, histone acetylation inhibitory activity, and modulatory activity of 
expression of genes and proteins involved in different breast carcinogenesis pathways. 
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Obtained results from all these studies make lunasin a good candidate for new generation of 
cancer preventive agents derived from foods. However, there is still much to be learned 
about lunasin’s effects on cancer prevention. The major challenge on the use of lunasin in 
treating cancer would be the conversion of in vitro and in vivo results into clinical outcomes. 
Therefore, it should be needed to design clinical trials that confirm lunasin’s 
chemopreventive properties against breast cancer. Other aspects, such as searching for 
lunasin in other seeds, optimization of techniques to enrich products with this peptide and 
studying lunasin's interactions with other food constituents affecting its activity should also 
be conducted. 
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